Allopurinol, furosemide and a phytotherapeutic agent (Bazoton uno) reverse P-glycoprotein-mediated doxorubicin resistance in human uterine sarcoma MES-SA/Dx5 cells: a novel therapeutic perspective
Angelini, A.; Centurione, M.A.; Di Pietro, R.; Centurione, L.
Journal of Biological Regulators and Homeostatic Agents 33(3): 991-997
2019
ISSN/ISBN: 0393-974X PMID: 31162035 Document Number: 698931
Document emailed within 1 workday
Related Documents
Baas, F.; Jongsma, A.P.; Broxterman, H.J.; Arceci, R.J.; Housman, D.; Scheffer, G.L.; Riethorst, A.; van Groenigen, M.; Nieuwint, A.W.; Joenje, H. 1990: Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line Cancer Research 50(17): 5392-5398Xu, H.-B.; Li, L.; Liu, G.-Q. 2009: Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells Die Pharmazie 64(10): 660-665
Mankhetkorn, S.; Dubru, F.; Hesschenbrouck, J.; Fiallo, M.; Garnier-Suillerot, A. 1996: Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells Molecular Pharmacology 49(3): 532-539
Weber, J.M.; Sircar, S.; Horvath, J.; Dion, P. 1989: Non-p-glycoprotein-mediated multidrug resistance in detransformed rat cells selected for resistance to methylglyoxal bis(guanylhydrazone) Cancer Research 49(21): 5779-5783
Gruber, A.; Larsson, R.; Nygren, P.; Björkholm, M.; Peterson, C. 1994: A non-P-glycoprotein-mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells Leukemia 8(6): 985-989
Stefanková, Z.; Barancík, M.; Breier, A. 1996: Overcoming of P-glycoprotein mediated vincristine resistance of L1210/VCR mouse leukemic cells could be induced by pentoxifyline but not by theophylline and caffeine Neoplasma 43(1): 11-15
Ferrari, L.A.; Bliven, S.F.; Wiemann, M.; Calabresi, P.; Glicksman, A.S.; Leith, J.T. 1986: Induction of doxorubicin resistance in heterogeneous human colon tumor cells by N-methylformamide Cancer Treatment Reports 70(10): 1177-1180
Kang, Y.; Perry, R.R. 1994: Effect of alpha-interferon on P-glycoprotein expression and function and on verapamil modulation of doxorubicin resistance Cancer Research 54(11): 2952-2958
Bellamy, W.T.; Dalton, W.S.; Kailey, J.M.; Gleason, M.C.; McCloskey, T.M.; Dorr, R.T.; Alberts, D.S. 1988: Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage Cancer Research 48(22): 6365-6370
Ferreira, M-José.U.; Duarte, Nélia.; Gyémánt, N.; Radics, R.; Cherepnev, G.; Varga, A.; Molnár, J. 2006: Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells Anticancer Research 26(5a): 3541-3546
Fu, J.; Chen, Z.; Cen, J.; Ruan, C. 2000: Expression of the human multidrug resistance gene mdr1 in leukemic cells and its application in studying P-glycoprotein antagonists Chinese Medical Journal 113(3): 228-231
Chen, A.Y.; Yu, C.; Potmesil, M.; Wall, M.E.; Wani, M.C.; Liu, L.F. 1991: Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells Cancer Research 51(22): 6039-6044
Bodey, B.; Taylor, C.R.; Siegel, S.E.; Kaiser, H.E. 1995: Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression Anticancer Research 15(6b): 2461-2468
Childs, S.; Yeh, R.L.; Hui, D.; Ling, V. 1998: Taxol resistance mediated by transfection of the liver-specific sister gene of P-glycoprotein Cancer Research 58(18): 4160-4167
Dantzig, A.H.; Shepard, R.L.; Cao, J.; Law, K.L.; Ehlhardt, W.J.; Baughman, T.M.; Bumol, T.F.; Starling, J.J. 1996: Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979 Cancer Research 56(18): 4171-4179
Qi, S.-N.; Song, L.-J.; Chen, Y.; Jing, Y.-X. 2010: Reversal of mdr1-mediated multidrug resistance in human leukemia cells by a new spin-labeled derivative of podophyllotoxin Die Pharmazie 65(2): 117-121
Chiba, P.; Ecker, G.; Schmid, D.; Drach, J.; Tell, B.; Goldenberg, S.; Gekeler, V. 1996: Structural requirements for activity of propafenone-type modulators in P-glycoprotein-mediated multidrug resistance Molecular Pharmacology 49(6): 1122-1130
Tobey, R.A.; Tesmer, J.G. 1985: Differential response of cultured human normal and tumor cells to trace element-induced resistance to the alkylating agent melphalan Cancer Research 45(6): 2567-2571
Murakami-Mori, K.; Mori, S.; Bonavida, B.; Nakamura, S. 1999: Implication of TNF receptor-I-mediated extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation in growth of AIDS-associated Kaposi's sarcoma cells: a possible role of a novel death domain protein MADD in TNF-alpha-induced ERK1/2 activation in Kaposi's sarcoma cells Journal of Immunology 162(6): 3672-3679
Vibrans, U.; Petres, J. 1972: Vincristine sulfate as a therapeutic agent in reticulum cell sarcoma Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 23(4): 171-174